BioCryst Pharma (BCRX) Misses Q4 EPS by 5c, Miss on Revenues; Offers FY18 Financial Guidance & Clinical Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 7.73 -0.02 (0.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.75 | 52 Week High | $10.98 | |||
| Open | $7.78 | 52 Week Low | $1.63 | |||
| Day High | $7.88 | P/E | N/A | |||
| Day Low | $7.66 | EPS | $-0.68 | |||
| Volume | 1,725,738 | |||||
